Rein Therapeutics Inc. (RNTX) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.
The consensus price target is $6.00, representing an upside of 268.1% from the current price $1.63.
Analysts estimate Earnings Per Share (EPS) of $-1.75 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.51 vs est $-1.75 (missed -101.1%). 2025: actual $-1.96 vs est $-0.93 (missed -110.8%). Analyst accuracy: 49%.
RNTX Stock — 12-Month Price Forecast
$6.00
▲ +268.10% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for Rein Therapeutics Inc., the price target is $6.00.
The average price target represents a +268.10% change from the last price of $1.63.
RNTX Analyst Ratings
Hold
Based on 1 analysts giving stock ratings to Rein Therapeutics Inc. in the past 3 months
EPS Estimates — RNTX
49%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.51
vs Est –$1.75
▼ 50.3% off
2025
Actual –$1.96
vs Est –$0.93
▼ 52.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RNTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
